en.Wedoany.com Reported - Data released at the Fourth AGP and DTx Summit held in Shenzhen shows that digital therapy can reduce glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes by an average of 0.54 percentage points, confirming its effectiveness in structured diabetes management.

In May 2026, the Fourth AGP and DTx Summit concluded in Shenzhen under the theme "Beyond Glucose." Co-hosted by SIBIONICS, the summit brought together international experts, healthcare professionals, researchers, educators, and patient representatives to explore how continuous glucose monitoring (CGM) data can shift from mere monitoring to generating clinical value.

A consensus reached during the summit was that CGM should not be viewed solely as a monitoring tool; its core value lies in transforming glucose data into clinical insights, treatment decisions, and meaningful behavioral changes.

In the progress report of the AGP and DTx Summit International Research and Development Alliance, Professor Andrej Janež noted that over the past two years, research funds have supported 20 investigator-initiated trials across 14 countries and regions. These studies focus on continuous glucose monitoring systems (CGM) and continuous ketone monitoring systems (CKM), covering topics such as accuracy in special populations, dietary patterns and glycemic responses, artificial intelligence platforms, and clinical monitoring applications.

Professor Sofianos Andrikopoulos emphasized the clinical role of digital therapies, noting that such therapies can integrate programmed interventions, lifestyle guidance, medication support, and comprehensive care models. Evidence presented at the summit indicated that the AGP and DTx Summit digital therapy is associated with an average HbA1c reduction of 0.54 percentage points, confirming its effectiveness in structured diabetes management.

Professor Wei Qiang demonstrated from a clinical phenotype perspective that combining routine admission parameters with CGM data and ambulatory glucose profile (AGP) helps identify metabolic phenotypes and treatment responses in hospitalized patients with type 2 diabetes, thereby enabling more personalized care.

Professor Shannon Lin pointed out that using CGM alone may encounter limitations, and data-based management is crucial. Research reflects strong interest from both physicians and patients in integrating CGM with artificial intelligence to generate predictive models and personalized recommendations. Professor Xiao Luo shared research findings that combining CGM with CKM can map glucose and ketone changes during fasting and feeding cycles, making metabolic interventions more feasible and practical.

Patient representative Tom Vesely, who has lived with type 1 diabetes for nearly 40 years, reminded the audience that CGM makes daily glucose fluctuations visible, but the goal should not only be better time in range (TIR), but more "happy time."

These discussions point to the next phase of diabetes care: moving from monitoring to change.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com